86 related articles for article (PubMed ID: 28195062)
1. The influence of the tumor necrosis factor-alpa-308G>A polymorphism on the efficacy of immunosuppressive therapy in patients after kidney transplantation.
M Kotowski M; Bogacz A; Bartkowiak-Wieczorek J; Sienko J; Procyk D; Dziewanowski K; Ostrowski M; Czerny B; Grzeskowiak E; Machalinski B
J Physiol Pharmacol; 2016 Dec; 67(6):819-826. PubMed ID: 28195062
[TBL] [Abstract][Full Text] [Related]
2. Genetic association of interleukin-2, interleukin-4, interleukin-6, transforming growth factor-β, tumour necrosis factor-α and blood concentrations of calcineurin inhibitors in Turkish renal transplant patients.
Seyhun Y; Ciftci HS; Kekik C; Karadeniz MS; Tefik T; Nane I; Turkmen A; Oguz FS; Aydin F
Int J Immunogenet; 2015 Jun; 42(3):147-60. PubMed ID: 25817300
[TBL] [Abstract][Full Text] [Related]
3. Influence of TGFB1 and CTLA4 polymorphisms on calcineurin inhibitors dose and risk of acute rejection in renal transplantation.
Bogacz A; Wolek M; Sieńko J; Czerny B; Machaliński B; Olbromski P; Kotowski M
Sci Rep; 2021 Sep; 11(1):17531. PubMed ID: 34475433
[TBL] [Abstract][Full Text] [Related]
4. Comparison of tacrolimus and cyclosporin A in CYP3A5 expressing Chinese de novo kidney transplant recipients: a 2-year prospective study.
Liu LS; Li J; Chen XT; Zhang HX; Fu Q; Wang HY; Xiong YY; Liu S; Liu XM; Li JL; Huang M; Wang CX
Int J Clin Pract Suppl; 2015 May; (183):43-52. PubMed ID: 26177348
[TBL] [Abstract][Full Text] [Related]
5. The Polymorphism -308G/A of
Sánchez-Fructuoso AI; Pérez-Flores I; Valero R; Moreno MA; Fernandez-Arquero M; Urcelay E; Fernández-Pérez C; Santiago JL
J Immunol Res; 2016; 2016():2197595. PubMed ID: 27777962
[TBL] [Abstract][Full Text] [Related]
6. Do drug transporter (ABCB1) SNPs influence cyclosporine and tacrolimus dose requirements and renal allograft outcome in the posttransplantation period?
Singh R; Srivastava A; Kapoor R; Mittal RD
J Clin Pharmacol; 2011 Apr; 51(4):603-15. PubMed ID: 20571034
[TBL] [Abstract][Full Text] [Related]
7. Cyclosporine A and tacrolimus combined with enteric-coated mycophenolate sodium influence the plasma mycophenolic acid concentration - a randomised controlled trial in Chinese live related donor kidney transplant recipients.
Huang HF; Yao X; Chen Y; Xie WQ; Shen-Tu JZ; Chen JH
Int J Clin Pract Suppl; 2014 Apr; (181):4-9. PubMed ID: 24673713
[TBL] [Abstract][Full Text] [Related]
8. The role of proinflammatory cytokine gene polymorphisms for development of insulin resistance after renal transplantation.
Gençtoy G; Kahraman S; Arici M; Altun B; Erdem Y; Bakkaloğlu M; Yasavul U; Turgan C
Transplant Proc; 2006 Mar; 38(2):521-8. PubMed ID: 16549165
[TBL] [Abstract][Full Text] [Related]
9. The effect of genetic variations for interleukin-10 (IL-10) on the efficacy of immunosuppressive therapy in patients after kidney transplantation.
Bogacz A; Polaszewska A; Bartkowiak-Wieczorek J; Tejchman K; Dziewanowski K; Ostrowski M; Czerny B; Grześkowiak E; Sieńko M; Machaliński B; Sieńko J; Kotowski M
Int Immunopharmacol; 2020 Dec; 89(Pt A):107059. PubMed ID: 33039969
[TBL] [Abstract][Full Text] [Related]
10. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
[TBL] [Abstract][Full Text] [Related]
11. Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation.
Zhang X; Liu ZH; Zheng JM; Chen ZH; Tang Z; Chen JS; Li LS
Clin Transplant; 2005 Oct; 19(5):638-43. PubMed ID: 16146556
[TBL] [Abstract][Full Text] [Related]
12. Optimizing tacrolimus therapy in the maintenance of renal allografts: 12-month results.
Bolin P; Shihab FS; Mulloy L; Henning AK; Gao J; Bartucci M; Holman J; First MR;
Transplantation; 2008 Jul; 86(1):88-95. PubMed ID: 18622283
[TBL] [Abstract][Full Text] [Related]
13. TNF-alpha and TGF-beta1 gene polymorphisms and renal allograft rejection in Koreans.
Park JY; Park MH; Park H; Ha J; Kim SJ; Ahn C
Tissue Antigens; 2004 Dec; 64(6):660-6. PubMed ID: 15546338
[TBL] [Abstract][Full Text] [Related]
14. Molecular and structural consequences of early renal allograft injury.
Baboolal K; Jones GA; Janezic A; Griffiths DR; Jurewicz WA
Kidney Int; 2002 Feb; 61(2):686-96. PubMed ID: 11849412
[TBL] [Abstract][Full Text] [Related]
15. Incidence of malignant neoplasia after heart transplantation--a comparison between cyclosporine a and tacrolimus.
Fuchs U; Klein S; Zittermann A; Ensminger SM; Schulz U; Gummert JF
Ann Transplant; 2014 Jun; 19():300-4. PubMed ID: 24953848
[TBL] [Abstract][Full Text] [Related]
16. Different renal toxicity profiles in the association of cyclosporine and tacrolimus with sirolimus in rats.
Lloberas N; Torras J; Alperovich G; Cruzado JM; Giménez-Bonafé P; Herrero-Fresneda I; Franquesa Ml; Rama I; Grinyó JM
Nephrol Dial Transplant; 2008 Oct; 23(10):3111-9. PubMed ID: 18469305
[TBL] [Abstract][Full Text] [Related]
17. Effect of CYP3A5 polymorphism on the pharmacokinetics of tacrolimus and acute rejection in renal transplant recipients: experience at a single centre.
Cheng Y; Li H; Meng Y; Liu H; Yang L; Xu T; Yu J; Zhao N; Liu Y
Int J Clin Pract Suppl; 2015 May; (183):16-22. PubMed ID: 26177012
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results.
Krämer BK; Montagnino G; Del Castillo D; Margreiter R; Sperschneider H; Olbricht CJ; Krüger B; Ortuño J; Köhler H; Kunzendorf U; Stummvoll HK; Tabernero JM; Mühlbacher F; Rivero M; Arias M;
Nephrol Dial Transplant; 2005 May; 20(5):968-73. PubMed ID: 15741208
[TBL] [Abstract][Full Text] [Related]
19. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
Gaber AO; Kahan BD; Van Buren C; Schulman SL; Scarola J; Neylan JF;
Transplantation; 2008 Nov; 86(9):1187-95. PubMed ID: 19005398
[TBL] [Abstract][Full Text] [Related]
20. Individualization of tacrolimus dosage basing on cytochrome P450 3A5 polymorphism--a prospective, randomized, controlled study.
Chen SY; Li JL; Meng FH; Wang XD; Liu T; Li J; Liu LS; Fu Q; Huang M; Wang CX
Clin Transplant; 2013; 27(3):E272-81. PubMed ID: 23432535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
